Nestlé India Falls 3% After Shocking FSSAI Baby Action
Summary
- Nestle India shares fell as much as 2.85% to ₹1,332.80 on the BSE on September 18 after FSSAI initiated legal action against the company.
- FSSAI has filed three separate adjudication cases against Nestlé India concerning infant nutrition products.
- The products under regulatory scrutiny include NAN Excella Pro Stage 1, Lactogen Pro 1 and a follow-up formula.
- FSSAI also raised concerns over promotional claims including “5 HMOs”, “Whey Protein” and “easy to digest” whey protein.
Nestle India Share Price Today: Why Did the Stock Fall?
Regulatory action and market response
Shares of nestle India share came under pressure during Friday’s trading session. On September 18, 2026, the FSSAI announced legal action over alleged non-compliances. However, this move heightened scrutiny of the company among investors and regulators. Market participants watched for guidance on regulatory expectations.
Investors anticipated further disclosures from the company. Officials emphasized adherence to food safety standards as the case develops. The update signaled that regulatory risk could shape the stock’s near-term trajectory. Stakeholders awaited official comments on timeline and remedies. Any statements could influence sentiment around the stock.
The stock fell as much as 2.85% to ₹1,332.80 per share on the BSE during the session. Reports on the regulatory action linked the decline to concerns surrounding three infant nutrition products and the findings of laboratory testing.
The development is significant because the regulatory action involves products intended for infant nutrition, an area subject to specific food safety, promotional and advertising requirements in India.
For readers tracking the broader market, this is another example of how regulatory developments can quickly become a factor in the movement of individual FMCG stocks.
Related reading: Latest Stock Market News
FSSAI Takes Legal Action Against Nestle India
According to FSSAI, it has initiated legal action against Nestlé India in connection with several non-compliances under the Food Safety and Standards Act.
The regulator has filed three separate adjudication cases concerning three products. The action followed both scrutiny of promotional material available on e-commerce platforms and laboratory testing of a follow-up formula manufactured by Nestlé India.
The three products or product categories involved are:
- NAN Excella Pro Stage 1
- Lactogen Pro 1
- A follow-up formula
The cases relate to different regulatory concerns, including promotional claims made for infant nutrition products and the Biotin content found in a laboratory-tested sample.
What Did FSSAI Find in Nestle Baby Products?
FSSAI examined the infant nutrition products as well as promotional material available through e-commerce platforms.
In the case of NAN Excella Pro Stage 1, the regulator flagged claims relating to “5 HMOs” and “Whey Protein.”
For Lactogen Pro 1, FSSAI raised concerns over a claim describing the whey protein as easy to digest.
The regulator said it sought clarification from Nestlé India regarding these claims. According to FSSAI, the products were found to be in contravention of Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020.
FSSAI also referred to Section 3 of the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992, which restricts the advertising and promotion of infant milk substitutes and infant foods covered by the legislation.
Biotin Content Issue in Follow-Up Formula
Separately, FSSAI said that a sample of a follow-up formula manufactured by Nestlé India was found to be sub-standard for Biotin content during laboratory testing.
The sample was subsequently sent for re-analysis. The referral laboratory also found that the sample did not conform to the Biotin requirement prescribed under the applicable 2020 regulations.
This finding forms a separate part of the regulatory action against the company.
Nestle India Share Price Performance
Market Update
The regulatory development added pressure on nestle India share during Friday’s session.
The shares touched an intraday low of ₹1,332.80 on the BSE, representing a decline of approximately 2.85% from the previous level.
According to the figures reported on September 18, 2026, Nestlé India’s stock had recorded the following performance:
- 1 week: Down around 3%
- 1 month: Down around 8%
- 4 months: Down around 4%
- 6 months: Up around 11.5%
- 1 year: Up around 11%
- 5 years: Up around 33%
The stock had previously touched a 52-week high of ₹1,553 in August 2026, while its 52-week low was around ₹1,145.10 in October 2025.
Stock prices can change throughout the trading session, so investors should refer to the latest NSE/BSE data for the current market price rather than relying on intraday figures reported earlier in the day.
More Stories
ixigo Q2 Results: Profit Reaches ₹63.42 Crore, Revenue Rises 13% as Hotels Business Expands
FPI Outflows October 2026: Foreign Investors Withdraw ₹52,100 Crore From Indian Stocks
Paras Healthcare IPO 2026: ₹1,450 Crore Issue, Price Band, Dates and Review
57th GST Council Meeting 2026: Major Reforms Proposed for Taxpayers and Businesses
Why the FSSAI Action Matters for Nestle India
The regulatory action is important for Nestlé India because the products involved are part of its infant nutrition portfolio, where advertising, promotional communication and product composition are subject to specific regulatory requirements.
The issue is not limited to the stock-market reaction. FSSAI’s action covers three separate adjudication cases, meaning the regulatory process will determine the consequences of the alleged non-compliances.
Investors should therefore distinguish between the immediate share-price reaction and the eventual outcome of the regulatory proceedings.
At the time of reporting, the publicly reported information cited the FSSAI findings and legal action; it does not establish that the adjudication process has reached a final conclusion against Nestlé India.
Nestle India Q1 FY27 Performance
The FSSAI development comes after Nestlé India reported strong financial numbers for the June quarter.
According to market reports, the company reported standalone net profit of ₹975.12 crore in Q1 FY27, compared with ₹659.23 crore in Q1 FY26, representing a year-on-year increase of about 47.92%.
Revenue from operations increased to ₹6,378.18 crore, compared with ₹5,096.16 crore in the corresponding quarter of the previous financial year.
This financial performance provides broader context when looking at the company’s stock movement. However, quarterly financial performance and regulatory developments are separate factors and should not be treated as directly offsetting one another.
What Investors Should Watch Next
The key developments to watch following the FSSAI action include:
1. Regulatory proceedings: The three adjudication cases will determine the next stage of action and any consequences arising from the alleged non-compliances.
2. Company response: Any clarification or response from Nestlé India regarding the products, promotional claims and Biotin findings could become relevant for investors and consumers.
3. Product-related developments: Investors may monitor whether there are any changes involving the affected infant nutrition products.
4. Stock-market reaction: Nestle India share price could continue to respond to fresh regulatory disclosures, company announcements and broader FMCG-sector sentiment.
5. Financial performance: Future quarterly results will remain important for assessing the company’s underlying business performance alongside the regulatory issue.
Nestle India FSSAI Action: Key Takeaways
The FSSAI action against nestle India share involves three adjudication cases related to infant nutrition products. The regulator’s actions focus on adherence to labeling standards, advertising claims, and consumer safety protocols, reflecting a broader effort to ensure accurate information reaches parents and caregivers.
Additionally, the regulator has raised concerns over promotional claims associated with NAN Excella Pro Stage 1 and Lactogen Pro 1, and has separately reported a laboratory finding involving Biotin content in a follow-up formula, which may influence regulatory assessments and consumer trust.
Nestlé India’s shares fell nearly 3% during Friday’s trading session, touching ₹1,332.80 on the BSE. However, the share-price movement represents the market’s reaction at that point in trading and should not be interpreted as the final financial impact of the regulatory proceedings.
Investors should follow official company disclosures, stock-exchange filings and subsequent updates from FSSAI for further developments.
Disclaimer: EduTaxTuber provides content for general educational and informational purposes only. While we make reasonable efforts to keep the information accurate and updated, laws, regulations, market conditions, software features, and other information may change. Some content may be created or assisted by AI tools and may contain errors or omissions. Readers should verify important information with official sources or qualified professionals before making any tax, legal, financial, investment, business, or other decisions. EduTaxTuber does not guarantee the completeness or accuracy of the information and does not provide professional advice.
